Ocugen Announces Positive Preliminary Phase 2 Data for OCU410 Gene Therapy in Dry Age-Related Macular Degeneration

Ocugen announced positive preliminary data from its Phase 2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The trial showed a 46% lesion growth reduction at 12 months, with no serious adverse events reported. The therapy targets multiple pathways associated with GA, offering a promising alternative to current treatments.